Physician profile
James Gramling
NPI 1366842015
$5,822.71
in general payments reported to CMS, 2019-2025
33 companies · $1,763 in 2025
The $1,763 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2022: $775 · 2023: $1,057 · 2024: $2,038 · 2025: $1,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,838 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,837.69 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $787.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $709.92 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $674.81 | 2021-2025 | |
| Lilly USA, LLC | $567.23 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $469.37 | 2023-2025 | Gemtesa |
| Abbvie INC. | $438.31 | 2022-2025 | |
| Glaxosmithkline, LLC. | $288.48 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $266.29 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.31 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $187.98 | 2023-2025 | Rexulti |
| Amgen INC. | $174.00 | 2023-2025 | Krystexxa, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.03 | 2022-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $125.41 | 2024-2025 | Veozah |
| Boston Scientific Corporation | $117.67 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.96 | 2021-2024 | Trintellix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $71.24 | 2024-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $60.13 | 2024-2025 | Austedo Xr, Austedo Xr |
| Xeris Pharmaceuticals, INC. | $57.57 | 2023-2024 | Keveyis |
| Janssen Pharmaceuticals, INC | $51.09 | 2022 | |
| Shield Therapeutics INC | $39.54 | 2023-2024 | Accrufer |
| Amarin Pharma, INC. | $33.51 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $33.38 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.49 | 2025 | Caplyta |
| Pulmonx Corporation | $30.89 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Horizon Therapeutics Plc | $21.29 | 2023 | Krystexxa |
| Antares Pharma, INC. | $19.80 | 2024 | Xyosted |
| Exact Sciences Corporation | $19.09 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $17.36 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.95 | 2022 | |
| Lundbeck LLC | $15.41 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2025 | Zoryve |
| Irhythm Technologies, INC. | $12.58 | 2022 | |
| Abbott Laboratories | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gramling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.